Recent News/Events/Press Releases

A Sampling of Abstracts from the Myeloma Institute Accepted for Presentation at the 47^th annual meeting of the American Society of Hematology, December 10-13, 2005 in Atlanta, Georgia

Oral Presentations

John Shaughnessy, PhD
Interphase FISH-defined amplification of chromosome 1q21 identify high risk subsets among patients with MM lacking metaphase cytogenetic abnormalities

Guido Tricot, MD, PhD
Melphalan 200mg/m² and MEL 140/DT-PACE are equally effective in MM while the latter is less toxic

TT2 for MM: thalidomide effects superior complete response and event-free survival; similar overall survival linked to shorter post-relapse survival

Low frequency of treatment-related myelodysplastic syndromes after autotransplants for MM especially if AT is applied early during treatment

Shmuel Yaccoby, PhD
Reciprocal interaction between megakaryocytes and myeloma cells results in increased survival and proliferation of myeloma cells

Inhibition of DKK1 activity is associated with increased osteoblast numbers and bone formation, reduction osteoclast activity and inhibition of tumor growth in the SCID-hu model for primary myeloma

Yang Yang, MD, PhD (UAMS Department of Pathology)
Heparanase upregulates synthesis and expression of syndecan-1 – a novel growth regulatory loop for myeloma tumors

Maurizio Zangari, MD
The anti-myeloma effect of bortezomib is associated with osteoblast activity

Poster Presentations

Bart Barlogie, MD, PhD
TT1: status report of the first tandem autotransplant for MM – 15 yrs later

TT2 is superior to T1 for newly diagnosed MM: doubling 4-yr survival among patients with cytogenetic abnormalities due to consolidation chemotherapy and DEX maintenance

TT3 incorporating Velcade into upfront management of MM: comparison with TT2 + thalidomide

Shorter post-relapse survival of myeloma patients randomized to the thalidomide arm of TT2 related to chromosome 1q21 amplification at relapse

Federica Cavallo, MD (visiting physician from University of Turin, Italy)
Variables predicting for poor mobilization of peripheral blood stem cells in newly diagnosed myeloma patients treated on TT2

Serum free-lite chain assay in MM: clinical correlates and prognostic implications in newly diagnosed MM patients treated with TT2 or 3

Frits van Rhee, MD, PhD
Arkansas autotransplant experience with >2500 myeloma patients: follow-up extending to >15 years

Ronald Walker, MD (UAMS Department of Radiology)
Correlation of suppression of FDG PET uptake with serum free light chain levels: both FDG PET-CT and serum clonal free light chain response precede and predict the likelihood of subsequent complete remission in newly diagnosed MM

Fenghuang Zhan, MD, PhD
The gene expression signatures of whole bone marrow biopsies from patients with MM in remission reflect disease risk and therapy

Beta-catenin and N-cadherin in myeloma: implications for adhesion and migration

Having problems with the site? E-mail the Webmaster.
Copyright 2002-2005, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences
Terms and Conditions of Use

The information on the Myeloma Institute web site is not intended as a substitute for professional medical attention. The information is intended only as an aid in understanding current medical knowledge. A physician should always be consulted for any health concern or medical condition. The Myeloma Institute web site provides links to other organizations as a service to our readers. The Myeloma Institute is not responsible for the information provided on other web sites.